DEF: Centessa Pharmaceuticals Seeks Shareholder Approval for Director Re-elections and Remuneration Policies at 2025 AGM

Centessa Pharmaceuticals is holding its Annual General Meeting on June 20, 2025, seeking shareholder approval for director re-elections, auditor appointments, and remuneration policies.

Summary

• Centessa Pharmaceuticals plc will hold its 2025 Annual General Meeting (AGM) on June 20, 2025, in London.
• Shareholders will vote on ten resolutions, including the re-appointment of directors Arjun Goyal and Samarth Kulkarni, the re-appointment and ratification of KPMG as auditors, and the approval of the directors' remuneration report and policy.
• The directors recommend voting in favor of all resolutions.
• The meeting will address the authorization for the allotment of shares and the disapplication of preemptive rights, seeking shareholder approval to issue new shares without offering them to existing shareholders first.
• The company's issued ordinary share capital as of April 25, 2025, consisted of 133,598,369 ordinary shares.
• A quorum requires at least 33 1/3 percent of issued shares to be represented.
• The Board of Directors is seeking authority to allot shares up to an aggregate nominal amount of 133,184, representing approximately 49.84% of the issued share capital as of April 24, 2025.
• The Board of Directors is seeking power to allot shares for cash or to grant rights to subscribe for or to convert any security into shares without first offering them to existing shareholders in proportion to their existing holdings up to an aggregate maximum nominal amount of 133,184.

Sentiment

Score: 7

Explanation: The document is largely procedural, outlining the resolutions for the AGM. The board's recommendation to vote in favor of all resolutions suggests a positive outlook, but the document itself is neutral in tone.

Positives

• The Board of Directors unanimously recommends shareholders vote in favor of all resolutions, indicating confidence in the company's direction.
• The company is seeking flexibility to finance business opportunities and growth by issuing shares or granting rights over shares without a pre-emptive offer to existing shareholders.
• The proposed changes to the remuneration policy are intended to ensure the policy remains sufficiently flexible for the future.

Negatives

• Approval of Proposals 9 and 10 by shareholders will not exempt the Company from any Nasdaq corporate governance or other requirements, including those limiting the issuance of shares.
• The company discontinued the global clinical development of SerpinPC, a novel inhibitor of activated protein C that was being evaluated for the treatment of hemophilia B.

Risks

• Failure to secure shareholder approval for the resolutions could hinder the company's strategic flexibility.
• The company faces the risk of being at a competitive disadvantage compared to its peer companies, many of whom are incorporated in the United States.
• The company faces the risk of not being able to attract and retain high caliber talent.

Future Outlook

The company plans to continue to add additional talent in 2025 and is focused on executing the ORX750 Phase 2a CRYSTAL-1 study which is on track with data expected in 2025.

Management Comments

• Your Directors consider that each Resolution is in the best interests of the Company and its shareholders as a whole and is likely to promote the success of the Company.
• Accordingly, your Directors unanimously recommend that you vote in favor of the Resolutions as each of the Directors with personal holdings of equity interests in the Company intends to do in respect of their own beneficial holdings.

Industry Context

The document highlights the competitive landscape of the pharmaceutical industry, particularly in relation to capital raising and the need for flexibility in issuing shares, noting that US-incorporated companies are not required to offer shares to existing shareholders on a pre-emptive basis.

Comparison to Industry Standards

• The document notes that the Board of Directors is mindful of the fact that equivalent United States incorporated companies are not required to offer shares to existing shareholders on a pre-emptive basis in the event they are pursuing an equity fundraising.
• The Board of Directors considers that this may place the Company at a competitive disadvantage.
• Many of our strategic competitors are incorporated in the United States where they are not subject to restrictions on their ability to issue shares.

Stakeholder Impact

• Shareholders are asked to vote on resolutions that will impact the company's governance and financial flexibility.
• Employees may be affected by the company's decisions regarding capital allocation and strategic priorities.

Next Steps

• Shareholders to vote on the resolutions at the Annual General Meeting on June 20, 2025.
• The Board of Directors will present the UK statutory annual accounts and reports for the financial year ended December 31, 2024, at the AGM.
• The company will make available the results of any polls taken on the resolutions at the AGM on its website.

Key Dates

Keywords

Annual General Meeting, Proxy Statement, Shareholder Vote, Director Re-appointment, Auditor Appointment, Remuneration Policy, Share Allotment, Preemptive Rights, Centessa Pharmaceuticals, Corporate Governance